Use of magnoflorine-phospholipid complex to permeate blood-brain barrier and treat depression in the CUMS animal model.

Use of magnoflorine-phospholipid complex to permeate blood-brain barrier and treat depression in the CUMS animal model.
Drug Deliv. 2019 Dec;26(1):566-574
Authors: Li B, Han L, Cao B, Yang X, Zhu X, Yang B, Zhao H, Qiao W
Abstract
To improve the liposolubility and blood-brain barrier permeability of magnoflorine, a new formulation of magnoflorine-phospholipid complex was prepared, characterized, and pharmacologically evaluated in the chronic unpredictable mild stress animal model. In this paper, the magnoflorine-phospholipid complex was synthesized and its characterization was determined. The antidepressant-like and antioxidant activity of magnoflorine-phospholipid complex was investigated by behavioral tests and western blotting analysis. As a result, the magnoflorine-phospholipid complex displayed high encapsulation efficiency and significantly improved the oil-water participate coefficient. In vivo blood-brain distribution study, the magnoflorine-phospholipid complex extended the duration of magnoflorine in blood and help magnoflorine to permeate the blood-brain barrier into brain. In behavioral tests, the magnoflorine-phospholipid complex significantly decreased immobility time compared to model control group in both FST and TST. Furthermore, the magnoflorine-phospholipid complex increased the expression of antioxidative stress-related proteins by the western blotting analysis. These findings strongly suggest that the phospholipi...

Source: Drug Delivery - May 21, 2019 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research